Sight Sciences reaffirms revenue guidance expectations for full year 2024 of approximately $81M to $85M, representing growth of approximately 0% to 5% growth compared to 2023. The Company continues to expect double-digit revenue growth in the second half of 2024 compared to the same period in the prior year as it regains commercial momentum and expands utilization and its customer base. The Company reaffirms its guidance expectations for adjusted operating expenses for full year 2024 of approximately $107M to $110M representing a decrease of approximately 0% to 3% compared to 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGHT:
- Sight Sciences Enhances Transparency with Strategic Financial Moves
- Sight Sciences announces $34M patent infringement verdict against Alcon
- Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery
- Sight Sciences to Report First Quarter Financial Results on May 2, 2024
- Sight Sciences publishes results from MIGS study in AJO